18.32
-0.35 (-1.87%)
| 前收盘价格 | 18.67 |
| 成交量 | 1,533,600 |
| 预期市盈率 (P/E Forward) | 20.38 |
| 价格/销量 (P/S) | 2.70 |
| 股市价格/股市净资产 (P/B) | 2.34 |
| 52周波幅 |
| 营业毛利率 | 22.97% |
| 营业利益率 (TTM) | 7.90% |
| 稀释每股收益 (EPS TTM) | 1.37 |
| 季度收入增长率 (YOY) | 18.70% |
| 季度盈利增长率 (YOY) | 14.70% |
| 总债务/股东权益 (D/E MRQ) | 7.32% |
| 流动比率 (MRQ) | 2.88 |
| 营业现金流 (OCF TTM) | 148.96 M |
| 杠杆自由现金流 (LFCF TTM) | 19.27 M |
| 资产报酬率 (ROA TTM) | 5.56% |
| 股东权益报酬率 (ROE TTM) | 37.24% |
新闻情绪
- What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings Call
- Acadia Pharmaceuticals (ACAD) Tops Q3 Earnings and Revenue Estimates
AIStockmoo 评分
| 价值 30% | 1.2 |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对其盈利增长,估值偏高。 参考 | |
| 当前股价隐含每年 -4.4% 的盈利增长;公司业务可支撑约每年 15.0% 的增长。 参考 | |
| 历史估值 参考 | NA |
| 负债低。盈利能力强。短期流动性充足。现金流为正。 参考 | |
| 资本回报低于资本成本。资本回报上升。 参考 | |
| 时机 30% | -1.9 |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 过去一年呈下降趋势。股价远低于52周高点。 参考 | |
| 近期出现看涨反转形态:看涨吞没。 参考 | |
| 您持有期的趋势 参考 | NA |
| 市场情绪 20% | 0.3 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻好坏参半或中性。 参考 | |
| 聪明钱 20% | -0.7 |
| 内部交易活动 参考 | NA |
| 机构在最新13F申报中净-0.57%的股份:216家增持,159家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化-14.6%,回补天数5.9天(FINRA)。 参考 | |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向不一,评分因此减弱。 | |
| 不计入评分 | |
| 股价低于其52周平均水平。 参考 | |
| 短期动能下降。 参考 | |
| 股价处于支撑位与阻力位之间。 参考 | |
| 最终评分 | -0.31 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | ACADIA Pharmaceuticals Inc. | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B |
|---|---|---|---|---|
| ACAD | - | - | - | 2.34 |
| FOLD | 5 B | - | - | - |
| IGMS | 71 M | - | - | 0.760 |
| SLGL | - | - | - | 3.80 |
| COGT | - | - | - | 11.00 |
| CYTK | - | - | - | - |
|
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.57% |
| 机构持股比例 | 104.46% |
该时间范围内无数据。
该时间范围内无数据。
机构
机构持股比例: 106.56%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 216 | 14,490,539 |
| 减持 | 159 | 14,311,770 |
| 新建仓 | 66 | 2,351,806 |
| 清仓 | 59 | 3,514,997 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 8,317,392 | 5.9 |
| 15 Oct 2026 | 9,094,151 | 4.6 |
| 30 Sep 2026 | 8,275,918 | 2.9 |
| 15 Sep 2026 | 9,666,972 | 7.2 |
| 31 Aug 2026 | 9,739,720 | 6.9 |
| 14 Aug 2026 | 9,478,912 | 4.5 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 17 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
SAN DIEGO, November 17, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today presented additional data from the Phase 2 RADIANT trial evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) during an oral presentation at the… |
| 16 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan
SAN DIEGO, November 16, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it has entered into an exclusive distribution agreement with KYORIN Pharmaceutical Co., Ltd. (TSE: 4569), for the commercialization of DAYBUE® STIX (trofinetide) powder for oral solution in Japan for the… |
| 10 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals Fell While Sales Rose
Acadia Pharmaceuticals ended Q3 2026 touting a revenue beat, stronger Daybue and Nuplazid sales, and fresh guidance pointing to full year revenue between US$1.26b and US$1.3b. Holding Acadia Pharmaceuticals from the start of the year would have meant a 37.2% loss, including dividends. If you had… |
| 09 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
SAN DIEGO, November 10, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today reported that oral arguments were held before the U.S. Court of Appeals for the Federal Circuit in the appeal of the U.S. District Court for the District of Delaware’s May 2025 decision upholding Acadia’s U.S. Patent No.… |
| 09 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals (ACAD) Stock Still Looks Like A Bargain Today
Acadia Pharmaceuticals shares have dropped sharply so far in 2026, raising a clear question for investors who watch valuation closely. With the stock under pressure and earnings in focus, the issue is whether today's price fairly reflects what the business is currently earning. The share price is… |
| 09 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals (ACAD) Cuts 2026 R And D Guidance, Is It Still 46% Undervalued?
Acadia Pharmaceuticals (ACAD) just paired fresh quarterly results with a guidance tweak and new Alzheimer’s trial data, giving investors several moving parts to assess at the same time. The reaction has been harsh. Acadia Pharmaceuticals’ share price has fallen about 22% over the last day and is… |
| 09 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
SAN DIEGO, Calif., November 09, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present two data presentations related to Alzheimer's disease psychosis (ADP) and remlifanserin at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place November… |
| 05 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals Sees Continued Daybue Momentum in Q3, RBC Says
Acadia Pharmaceuticals (ACAD) reported Q3 results underpinned by continued Daybue growth and steady… |
| 05 Nov 2026 | Yahoo Finance |
ACADIA Pharmaceuticals Inc (ACAD) Q3 2026 Earnings Call Highlights: Record Daybue Sales and ...
ACADIA Pharmaceuticals Inc (ACAD) posted $342 million in quarterly revenue and lifted its Daybue outlook, even as the remlifanserin Phase 2 study narrowly missed statistical significance. |
| 04 Nov 2026 | Yahoo Finance |
What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings Call
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported third-quarter 2026 revenue of $342 million, up 22% from a year earlier on an adjusted basis, as demand for its Rett syndrome treatment DAYBUE and Parkinson’s disease psychosis drug NUPLAZID drove growth. The company raised its full-year DAYBUE sales out… |
| 04 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals (ACAD) Tops Q3 Earnings and Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of +63.16% and +2.22%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 04 Nov 2026 | Yahoo Finance |
Acadia: Q3 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Acadia Pharmaceuticals Inc. (ACAD) on Wednesday reported third-quarter earnings of $53… |
| 04 Nov 2026 | Yahoo Finance |
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
SAN DIEGO, November 04, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2026… |
| 29 Oct 2026 | Yahoo Finance |
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
| 28 Oct 2026 | Yahoo Finance |
Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
SAN DIEGO, October 28, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference 2026 on Tuesday, November 17, 2026 at 12:40 p.m. Greenwich Mean Time. |
| 28 Oct 2026 | Yahoo Finance |
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
| 21 Oct 2026 | Yahoo Finance |
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
SAN DIEGO, October 21, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on… |
| 21 Oct 2026 | Yahoo Finance |
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential. |
| 13 Oct 2026 | Yahoo Finance |
Top Midday Decliners
UBS downgraded Acadia Pharmaceuticals' (ACAD) shares one notch to neutral and set a $23 price target… |
| 13 Oct 2026 | Yahoo Finance |
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition. |
| 显示更多 | ||
投资组合